Clinical Trial Update: Study to Evaluate the Effect of AFQ056 in Obsessive Compulsive Disorder (OCD) Patients Resistant to Selective Serotonin Reuptake Inhibitor (SSRI) Therapy [Phase 2]

View source ↗

Summary

Phase 2 study evaluating AFQ056 in obsessive-compulsive disorder patients resistant to SSRI therapy was terminated; results were posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obsessive-compulsive Disorder

Drugs mentioned

• AFQ056 (mavoglurant)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Patient Diagnosed With OCD and Resistant to SSRI Treatment, Failed SSRI Over 12 Weeks at Appropriate Doses | Phase 2 | Status: TERMINATED | Results posted: 2016-07-21